Stereotaxis(US:STXS)2026-03-09 21:32Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled $8.6 million, a 36% increase from $6.3 million in Q4 2024 [30] - Full year 2025 revenue was $32.4 million compared to $26.9 million in 2024 [30] - Gross margin for Q4 and full year 2025 was approximately 50% and 53% respectively [31] - Operating loss for Q4 2025 was $5.6 million, improved from $7.6 million in Q4 2024 [32] - Negative free cash flow for the full year was $13.8 million, compared to $8.5 million in 2024 [33] Business Line Data and Key Metrics Changes - System revenue for Q4 was $3.3 million, up from $1.4 million in the prior year [30] - Recurring revenue for Q4 was $5.3 million, down from $9.4 million in the prior year [30] - Full year system revenue was $10.2 million compared to $8.6 million in the prior year [30] - Full year recurring revenue was $22.2 million, up from $18.3 million in the prior year [31] Market Data and Key Metrics Changes - The electrophysiology (EP) market is projected to grow from over $13 billion to $20 billion by 2030 [14] - The company views the market opportunity for robotics in EP as $2 billion [15] Company Strategy and Development Direction - The company aims to pioneer robotics in minimally invasive endovascular surgery, focusing on making its robot widely available and building an ecosystem of catheters [10][11] - Key strategic pillars include rapid installation of robots, reducing dependencies on third-party catheters, leveraging core technology for broader applications, and establishing a digital backbone for connectivity [10][11] - The company achieved regulatory approvals for the GenesisX robot and associated catheters, marking a significant milestone [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth in 2026, with expectations for quarterly revenue to ramp above $10 million in the latter half of the year [35] - The company anticipates a working capital benefit to cash flow in 2026 after significant investments in working capital in 2025 [36] - Management is optimistic about overcoming manufacturing challenges and expects to establish a strong foundation for future growth [29] Other Important Information - The company has a cash balance of $13.4 million and no debt as of December 31 [34] - Manufacturing challenges have been a focus, particularly with the MAGiC catheter, which faced production issues [22][74] Q&A Session Summary Question: What is the goal for GenesisX programs and sales expectations? - Management expects Genesis sales to continue at a similar pace as previous years, with mid-single digit numbers of Genesis systems sold annually [39] Question: What is the revenue goal for Synchrony in 2026? - The revenue goal includes capital sales and recurring revenue from service contracts and software subscriptions, with several hospitals expected to standardize their EP labs on Synchrony [43] Question: How is the allocation of MAGiC catheters being managed amid manufacturing constraints? - Management acknowledged the challenge of ramping manufacturing and is working to ensure that administrative efforts are in place to meet demand as production increases [49] Question: What are the economic models for GenesisX? - Three core models are being utilized: outright capital sale, leasing, and placement with disposable commitments, allowing flexibility in revenue generation [76] Question: What is the outlook for the Chinese market? - The company expects the first Genesis systems to be sold in China this year, with ongoing efforts to transition to new catheter systems and regulatory submissions [90]